Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $29.78

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned a consensus recommendation of “Buy” from the eleven research firms that are presently covering the company, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $29.78.

A number of analysts recently issued reports on the stock. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James assumed coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target for the company. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 target price on shares of enGene in a research report on Wednesday, September 11th. Finally, HC Wainwright assumed coverage on enGene in a research report on Monday, December 23rd. They set a “buy” rating and a $25.00 price target on the stock.

enGene Trading Up 6.2 %

NASDAQ:ENGN opened at $7.06 on Tuesday. enGene has a 52 week low of $4.42 and a 52 week high of $18.40. The firm has a 50-day moving average price of $7.69 and a two-hundred day moving average price of $7.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The firm has a market cap of $312.16 million, a price-to-earnings ratio of -12.17 and a beta of -0.78.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. On average, equities analysts expect that enGene will post -1.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other enGene news, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the business’s stock in a transaction on Monday, October 7th. The stock was acquired at an average cost of $6.55 per share, for a total transaction of $77,578.20. Following the completion of the transaction, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This represents a 0.48 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 13.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wolverine Asset Management LLC purchased a new position in shares of enGene in the third quarter worth $37,000. SR One Capital Management LP bought a new stake in enGene in the 2nd quarter worth $4,715,000. Point72 Asset Management L.P. increased its position in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. Franklin Resources Inc. raised its stake in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Finally, Logos Global Management LP boosted its holdings in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the period. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.